stockrow
Saturday 7 November 2026
Export ZBIO’s income statement to Excel — free account
Zenas BioPharma, Inc.
ZBIO Healthcare Biotechnology
Zenas BioPharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, up 100.0% from fiscal 2024.
- EPS
- −35.3%
- Free cash flow
- −41.0%
Quarter to September 2026, against a year earlier
28.26
2.33
+8.99%
Follow ZBIO
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | 0.00 | 0.00 |
P/S ratio |
— | — | 0.00 | 25.13 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (27.99) | (30.77) | |
P/B ratio |
— | — | 6.48 | 8.40 | |
Price to Tangible BV |
— | — | 6.48 | 8.40 | |
EV/Sales |
— | — | 0.00 | 22.36 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (5.96) | (6.54) | |
EV/FCF |
— | — | (5.96) | (6.54) | |
Quick Ratio |
5.48 | 11.73 | 9.77 | 9.14 | |
Current Ratio |
5.61 | 11.94 | 9.93 | 9.42 | |
Net Debt/EBITDA |
1.11 | 4.74 | 2.36 | 5.66 | |
Debt/Assets |
20.50% | 46.89% | 55.40% | 0.00% | |
Debt/Equity |
0.32 | 1.04 | 1.57 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.14 | |
Operating CF/Net income |
0.22 | 0.93 | 0.51 | 0.53 | |
Capex/Depreciation |
0.00 | (0.33) | 0.00 | (0.25) | |
Interest Coverage |
— | (11.66) | (10.45) | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 6,291.30% | 584.74% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 1,574.60% | 274.35% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 861.90% | 172.76% | |
Graham Net Nets |
— | — | 0.12 | 0.08 | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (35.42%) | (34.93%) | |
Free Cash Flow Yield |
— | — | (14.11%) | (13.61%) | |
Revenue per Share |
0.00 | 0.00 | 0.02 | 0.15 | |
Operating CF per Share |
(1.17) | (1.35) | (0.91) | (0.88) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.17) | (1.35) | (0.91) | (0.88) | |
Cash per Share |
7.67 | 12.89 | 10.19 | 8.85 | |
Shareholders Equity per Share |
5.41 | 6.04 | 3.92 | 3.21 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.41 | 6.04 | 3.92 | 3.21 | |
Free Cash Flow |
(52.41) | (75.20) | (57.24) | (57.98) | |
Working Capital |
288.52 | 669.00 | 587.98 | 539.41 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
209.68 | 318.31 | 199.20 | 140.54 | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
12.12 | 14.48 | 7.76 | 6.75 | |
Average Assets |
376.80 | 540.72 | 497.39 | 498.62 | |
Average Common Equity |
277.30 | 310.07 | 243.36 | 204.37 |
Columns are period end dates · fundamentals updated 5 Nov 2026